MiMedx Group, Inc Common Stock (MDXG) Stock
Key stats
- Market cap
- $484.47M
- Price / Earnings ratio
- -25.6x
- EPS (TTM)
- -$0.13
- Volume
- Loading
- 52-week high
- $7.66
- 52-week low
- $3.03
Source: third-party data provider, as of November 13, 2026
Compare with MDXG
Recent news

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
MDXG

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
MDXG

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MDXG

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MDXG
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 28.32
- MACD 12/26/9
- -0.32
- EMA 9 of MACD
- -0.29
- MACD histogram
- -0.03
- SMA 50
- $4.30
- Price below SMA 50
- EMA 50
- $4.06
- Price below EMA 50
- SMA 200
- $4.19
- Price below SMA 200
- EMA 200
- $4.56
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
MDXG

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
MDXG

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MDXG

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MDXG

MiMedx Group Q2 Earnings Call Highlights
MiMedx Group Q2 Earnings Call Highlights
MDXG

Is the Options Market Predicting a Spike in MiMedx Group Stock?
Is the Options Market Predicting a Spike in MiMedx Group Stock?
MDXG

MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MDXG

Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline
Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline
MDXG

MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MDXG

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products
MDXG
News tone: automated (AI) classification of the article's content, not a price prediction.
About MiMedx Group, Inc Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph H. Capper | CEO & Director | 1964 |
| Mr. Douglas C. Rice CPA | Chief Financial Officer | 1966 |
| Mr. William F. Hulse IV | General Counsel & Chief Administrative Officer | 1974 |
| Ms. Kimberly Maersk-Moller | Chief Commercial Officer | 1967 |
| Dr. John Harper Ph.D. | SVP of R&D & Medical Affairs and Chief Scientific Officer | — |
| Mr. Matthew M. Notarianni | Head of Investor Relations | — |
| Mr. Mark P. Graves | Senior VP & Chief Compliance Officer | 1966 |
| Ms. Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications | — |
| Mr. Eric A. Smith | Senior VP of Marketing & International | 1972 |
| Ms. Tracy Chastain | Chief Human Resources Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 28.32
- MACD 12/26/9
- -0.32
- EMA 9 of MACD
- -0.29
- MACD histogram
- -0.03
- SMA 50
- $4.30
- Price below SMA 50
- EMA 50
- $4.06
- Price below EMA 50
- SMA 200
- $4.19
- Price below SMA 200
- EMA 200
- $4.56
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $8.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.0 | -12.7 | ||||||||||
| 2022 | -20.9 | +2.2 | -6.2 | -18.6 | -1.0 | -8.0 | -4.2 | +3.5 | -17.8 | +0.0 | +7.6 | -15.0 |
| 2023 | +30.3 | +24.3 | -18.6 | +14.7 | +52.2 | +14.2 | +22.3 | -6.4 | -5.1 | -12.5 | +20.5 | +9.8 |
| 2024 | -1.7 | +3.6 | -10.8 | -17.3 | -2.2 | -2.4 | +11.2 | +2.4 | -7.4 | +16.1 | +33.5 | +2.6 |
| 2025 | -6.3 | -1.5 | -8.4 | -8.3 | +1.7 | -4.4 | +15.6 | -0.8 | -2.9 | +12.0 | -8.5 | +1.5 |
| 2026 | -21.1 | -3.9 | -19.1 | -14.9 | +0.0 | +7.5 | +5.9 | +6.3 | +3.1 | -16.4 | +1.2 |



